[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603374":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":35,"locations":42,"responsibleParty":70,"collaborators":72,"id":76,"slug":25,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":25,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":25,"enrollmentInfo":84,"targetDuration":25,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":98,"whyStopped":25,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Rush University Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Losartan","EXPERIMENTAL","The experimental arm (Arm 1) will receive 25mg losartan daily for 3 days followed by 50 mg losartan daily for 25 days.",[13],"Drug: Losartan",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","The placebo arm (Arm 2) will receive a placebo tablet with the same appearance and frequency to that of the losartan group.",[19],"Other: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Two types of losartan capsules will be compounded by combining a broken-up 25mg or 50mg losartan tablet and microcrystalline cellulose placebo filler to eliminate rattling of the broken tablet inside of the capsule. The 25mg losartan capsules will be yellow and the 50 mg losartan capsules will be blue.",[9],null,{"type":6,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"The placebo capsules will consist of microcrystal cellulose and will come in yellow and blue to appear identical to the losartan capsules.",[15],[30,33],{"name":31,"affiliation":5,"role":32},"Jorge Chahla, MD, PhD","PRINCIPAL_INVESTIGATOR",{"name":34,"affiliation":5,"role":32},"Andrew Bi, MD",[36,40],{"name":31,"role":37,"phone":38,"phoneExt":25,"email":39},"CONTACT","(312) 432-2452","Jorge.chahla@rushortho.com",{"name":34,"role":37,"phone":25,"phoneExt":25,"email":41},"Andrew.Bi@rushortho.com",[43],{"facility":5,"status":25,"city":44,"state":45,"zip":46,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Chicago","Illinois","60612","United States",{"type":49,"coordinates":50},"Point",[51,52],-87.65005,41.85003,{"lat":52,"lon":51},[55,57,59,61,63,66,68],{"name":56,"role":37,"phone":25,"phoneExt":25,"email":41},"Andrew BI, MD",{"name":31,"role":37,"phone":25,"phoneExt":25,"email":58},"Jorge.Chahla@rushortho.com",{"name":60,"role":32,"phone":25,"phoneExt":25,"email":25},"Jorge Chahla, MD PhD",{"name":62,"role":32,"phone":25,"phoneExt":25,"email":25},"Andrew Bi, MD PhD",{"name":64,"role":65,"phone":25,"phoneExt":25,"email":25},"Adam Yanke, MD, PhD","SUB_INVESTIGATOR",{"name":67,"role":65,"phone":25,"phoneExt":25,"email":25},"Brian Cole, MD",{"name":69,"role":65,"phone":25,"phoneExt":25,"email":25},"Catherine Yuh, MD",{"type":71,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[73],{"name":74,"class":75},"Arthroscopy Association of North America (AANA)","UNKNOWN","100603374",false,"NCT07135687","Study to Use Oral Losartan to Decrease the Risk of Postoperative Scarring Following (ACL) Reconstruction","Oral Losartan to Decrease the Risk of Postoperative Arthrofibrosis Following Primary and Revision Anterior Cruciate Ligament Reconstruction","Inclusion Criteria:\n\n* Must be undergoing a primary ACLR with or without the following:\n* Chondroplasty\n* Synovectomy\n* Loose body removal\n* Removal of hardware\n* Meniscal surgery (excluding meniscal allograft transplantation\u002FMAT)\n* Lateral extra-articular tenodesis\n* Must have skeletal maturity in the distal femur and proximal tibial physes\n* Must be age 18 years or older at time of enrollment\n\nExclusion Criteria:\n\n* \\\u003C18 years at time of enrollment\n* No diagnosis of ACL tear\n* ACL repairs\n* Revision ACL reconstructions\n* Open distal femur or proximal tibia physes\n* Major concomitant procedures (such as osteotomy, MAT, or cartilage restoration surgery)\n* History of prior proximal or distal femur fracture (including those receiving nonoperative treatment)\n* History of prior ipsilateral femur or tibia osteomyelitis\n* Medical history\n* History of hypotensive disease, including postural orthostatic hypotension syndrome (POTS), autonomic dysreflexia, or Shy-Drager syndrome (aka multiple system atrophy), baseline hypotension \\\u003C90 systolic or \\\u003C60 diastolic mmHg.\n* History of significant hepatic disease (liver transplantation, cirrhosis of any cause, or any liver disease with Child-Pugh classification B or C) due to hepatic metabolism of ARBs.\n* Chronic kidney disease\n* Rheumatologic disorders on immunologic medications\n* Current medications including diuretics (i.e. furosemide), lithium, and spironolactone\n* Current hypertension with prescription of an ARB or ACE-I\n* Allergy to losartan\n* Current pregnancy or breastfeeding","ALL","18 Years",{"count":85,"type":86},144,"ESTIMATED","INTERVENTIONAL",[89],"PHASE4","The purpose of this study to investigate the effect of using losartan (a blood pressure lowering drug with anti-scarring properties) on preventing primary postoperative arthrofibrosis (formation of abnormal scar tissue) in the knees in participants undergoing anterior cruciate ligament (ACL) repair surgery of their knee.",[92,93,94],"ACL Injury","ACL Reconstruction","Scar Formation",[96,97,9],"ACL","Postoperative Arthrofibrosis","NOT_YET_RECRUITING","2025-12-09",{"date":101,"type":102},"2025-12-15","ACTUAL",{"date":104,"type":86},"2026-08",{"date":106,"type":86},"2028-12",{"name":5,"class":6},1]